Nitric Oxide Synthesis Pathways and Signalling
Nitric oxide (NO; radical gas; t1/2 seconds in vivo; synthesised by NOS enzymes (NOS1/nNOS (neuronal; constitutive; calmodulin-dependent; nM NO for synaptic signalling/LTP); NOS2/iNOS (inducible; macrophage/epithelium; NF-κB-driven; µM NO sustained; peroxynitrite (ONOO−) production in inflammation); NOS3/eNOS (endothelial; constitutive; Ser1177 Akt-phosphorylation → activated; Thr495 PKC-phosphorylation → inhibited; calmodulin Ca2+-dependent; picomolar-nM NO for vasodilation)) is the primary endothelium-derived relaxing factor (EDRF): NO → soluble guanylyl cyclase (sGC; α1β1 heterodimer; haem-Fe2+-dependent; NO binds haem → conformational change → GTP → cGMP) → cGMP → PKG (protein kinase G; MLCP activation → MLC dephosphorylation → smooth muscle relaxation; VASP phosphorylation → platelet inhibition; IP3R phosphorylation → intracellular Ca2+ reduction). eNOS coupling requires: L-arginine (substrate; Km ~3 μM; adequate supply from dietary arginine + citrulline-arginine recycling); BH4 (tetrahydrobiopterin; cofactor for heme Fe3+→Fe2+ reduction enabling O2 activation; BH4 oxidation → BH2 → eNOS uncoupling → O2•− instead of NO); FAD/FMN; Zn2+ (structural; Zn-tetrathiolate bridging at eNOS dimer interface); and HSP90 (chaperone; maintains eNOS open conformation for calmodulin/CaM binding; HSP90:eNOS complex essential for effective coupling).
Spirulina Mechanisms in Nitric Oxide Signalling
eNOS Activation: HSP90, Akt-Ser1177, and AMPK
eNOS activation (Ser1177 phosphorylation by Akt (VEGF/shear stress/insulin → PI3K → Akt) and AMPK (energy stress → AMPK → eNOS Ser1177); Thr495 dephosphorylation by calcineurin; CaM binding; HSP90 complex maintenance) is enhanced by spirulina through: (1) AMPK Thr172 phosphorylation (+25–40%) → eNOS Ser1177 phosphorylation (+20–30%) in endothelial cells; (2) PI3K-Akt pathway restoration via IRS-1 dephosphorylation/PTEN modulation → Akt Thr308/Ser473 → eNOS Ser1177 (in insulin-resistant/metabolic syndrome endothelium where Akt-eNOS signalling is impaired); (3) HSP90 stabilisation (Nrf2-GSH maintenance of HSP90 Cys residues; phycocyanin HSP90 client support) → eNOS:HSP90 complex preserved → efficient eNOS coupling and NO vs. O2•− production. Phycocyanin phenolic metabolites also directly modulate eNOS allosterically (phenolic-eNOS interaction at oxygenase domain; +15–25% eNOS activity in endothelial cell assays).
BH4 Preservation and eNOS Coupling
BH4 oxidation (BH4 → BH3•/BH2; by peroxynitrite (ONOO−; rate constant ~10&sup9; M−1s−1; most rapid BH4 oxidant; in vivo: eNOS-generated O2•− reacts with adjacent eNOS-generated NO → ONOO− → BH4 oxidation → further uncoupling: vicious cycle); by H2O2 (H2O2 + Fe → •OH → BH4 oxidation at C4a position)) causes eNOS uncoupling (BH2-bound eNOS → NADPH → O2 → O2•− instead of L-Arg+O2 → citrulline+NO) → both reduces NO production and increases oxidative stress (O2•− → ONOO− → more BH4 oxidation → more uncoupling: amplifying positive feedback). Spirulina preserves BH4 by: (1) Nrf2 → DHFR upregulation (dihydrofolate reductase; reduces BH2 → BH4 in salvage pathway; Nrf2 ARE element in DHFR promoter; +15–25% DHFR); (2) iNOS suppression (−30–45% iNOS protein) → peroxynitrite reduction (iNOS is the primary source of µM NO flux in inflammation → ONOO− production); (3) O2•− scavenging (SOD1/2 Nrf2 upregulation → O2•− → H2O2 before reacting with NO → ONOO− reduced). Net: BH4:BH2 ratio +15–25% → eNOS coupling maintained → NO vs. O2•− production preserved.
ADMA Reduction via DDAH Upregulation
ADMA (asymmetric dimethylarginine; endogenous eNOS inhibitor; generated by PRMT (protein arginine methyltransferase; dimethylates Arg residues on histones and RNA-binding proteins → ADMA released upon protein turnover); plasma ADMA 0.4–0.9 μM normally; elevated in: CKD (ADMA clearance impaired), endothelial dysfunction, oxidative stress (PRMT upregulated), and cardiometabolic disease (ADMA >0.7 μM independently predicts MACE); ADMA competes with L-arginine at eNOS substrate-binding site (Ki ~2–3 μM): despite L-arginine excess (>100 μM plasma), ADMA can significantly reduce eNOS activity (“arginine paradox”)) is cleared by DDAH1/2 (dimethylarginine dimethylaminohydrolase; hydrolysis of ADMA → L-citrulline + dimethylamine; DDAH1 (liver/kidney; accounts for ~75% ADMA degradation); DDAH2 (endothelium/heart)). Spirulina Nrf2 activation upregulates DDAH2 in endothelial cells (+15–20%); NF-κB suppression reduces PRMT2 inflammatory upregulation (−15–20% PRMT2-driven ADMA generation). Net: plasma ADMA −15–25% in MetS/CKD models → eNOS inhibition relief → NO bioavailability +10–20%.
iNOS Suppression and Peroxynitrite Prevention
iNOS (NOS2; expressed in macrophages, hepatocytes, SMCs, epithelium upon NF-κB/LPS/IFN-γ stimulation; generates µM NO continuously without calmodulin Ca2+ requirement; no feedback inhibition; sustained iNOS activity → ONOO− formation (NO + O2•− → ONOO−; k ~6×10&sup9; M−1s−1; thermodynamically favoured) → protein nitration (Tyr3-NO2), DNA strand breaks, BH4 oxidation, MnSOD nitration (Tyr34) inactivation, SIRT1 nitration, β-cell/islet inflammation) is suppressed by spirulina through: NF-κB IKKβ inhibition (−30–45% NF-κB) → iNOS transcription −30–45% (iNOS promoter has 3 κB binding sites); IFN-γ/STAT1 signal attenuation (−20–30% STAT1 phosphorylation; IFN-γ-GAS element in iNOS promoter). Peroxynitrite markers (3-nitrotyrosine (3-NT) protein adducts; 8-nitroguanosine RNA modification) −30–45% in spirulina-supplemented inflammatory models. This iNOS suppression concurrently preserves eNOS coupling (BH4), MnSOD activity, and SIRT1 deacetylase function.
Clinical Outcomes in Nitric Oxide Signalling
- Flow-mediated dilation (FMD; endothelial eNOS-NO function): +2–5% absolute (8–12 weeks)
- Plasma ADMA: −15–25%
- Systolic/diastolic blood pressure: −4–8 / −2–5 mmHg
- 3-Nitrotyrosine (peroxynitrite marker): −30–45%
- BH4:BH2 ratio (endothelial): +15–25%
- Platelet aggregation (NO-cGMP-VASP): −15–25%
Dosing and Drug Interactions
Hypertension/endothelial dysfunction: 5–10g daily for 8–16 weeks. PDE5 inhibitors (sildenafil, tadalafil): Spirulina eNOS-NO-cGMP elevation is upstream; PDE5 inhibitors prevent cGMP degradation downstream; mechanistically synergistic → monitor BP for hypotension at high spirulina doses (>8g) with PDE5i. sGC stimulators (riociguat, vericiguat): Both sGC stimulators and spirulina eNOS-NO work on sGC; additive cGMP production → monitor for hypotension. L-arginine supplements: Spirulina ADMA reduction relieves arginine-ADMA competition (arginine paradox relief); co-supplementation with L-arginine may not be needed at ADMA <0.5 μM; useful at ADMA >0.7 μM. Antihypertensives (ACEi, ARBs, CCBs): Spirulina eNOS-NO BP reduction is additive; modest BP-lowering (4–8 mmHg systolic); can complement antihypertensive therapy. Summary: FMD +2–5%, ADMA −15–25%, SBP −4–8 mmHg, 3-NT −30–45%; dosing 5–10g daily. NK concern: low.